IFNB1 and myeloid sarcoma: The induction of CNS-endogenous IFNβ is of particular interest, since drugs based on this cytokine are used as first-line therapy for MS (McGraw and Lublin, 2013) and several studies have shown a protective role for IFNβ in EAE (Teige et al., 2003; Prinz et al., 2008; Galligan et al., 2010; Melero-Jerez et al., 2019).